A Randomized, Double-Blind, Placebo-Controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-2)
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: United Therapeutics Corporation
- Phase: III
- Execution start: 30/09/2022
- End of execution: 30/05/2025
- IP: ANA DOLORES ROMERO ORTIZ